{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T14:55:45Z","timestamp":1786114545478,"version":"build-2736575974"},"reference-count":42,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.xcrm.2026.102743","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T16:22:17Z","timestamp":1775665337000},"page":"102743","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["GZR18, a GLP-1 analog with once-weekly or bi-weekly dosing for body weight management: A randomized, placebo-controlled, phase 1b\/2a trial"],"prefix":"10.1016","volume":"7","author":[{"given":"Linong","family":"Ji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leili","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruihua","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingxia","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuguang","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyuan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2026.102743_bib2","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/dom.12124","article-title":"Diabetes and cancer: two diseases with obesity as a common risk factor","volume":"16","author":"Garg","year":"2014","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.xcrm.2026.102743_bib3","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/obr.12872","article-title":"The challenge for global health systems in preventing and managing obesity","volume":"20","author":"Wolfenden","year":"2019","journal-title":"Obes. Rev."},{"key":"10.1016\/j.xcrm.2026.102743_bib4","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1001\/jama.2023.19897","article-title":"Obesity Management in Adults: A Review","volume":"330","author":"Elmaleh-Sachs","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.xcrm.2026.102743_bib5","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jacc.2017.11.011","article-title":"Obesity: Pathophysiology and Management","volume":"71","author":"Gadde","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.xcrm.2026.102743_bib6","first-page":"545","article-title":"Guideline for chronic weight management and clinical practice of anti-obesity medications (2024 version) (in Chinese)","volume":"40","year":"2024","journal-title":"Chin J. Endocrinol. Metab."},{"key":"10.1016\/j.xcrm.2026.102743_bib7","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13700","article-title":"Clinical practice guidelines for the management of overweight and obesity published internationally: A scoping review","volume":"25","author":"Gaskin","year":"2024","journal-title":"Obes. Rev."},{"key":"10.1016\/j.xcrm.2026.102743_bib8","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1016\/S0140-6736(16)00271-3","article-title":"Management of obesity","volume":"387","author":"Bray","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.xcrm.2026.102743_bib9","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.metabol.2018.10.010","article-title":"Pharmacotherapy of obesity: Available medications and drugs under investigation","volume":"92","author":"Pilitsi","year":"2019","journal-title":"Metabolism"},{"key":"10.1016\/j.xcrm.2026.102743_bib10","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S2213-8587(17)30236-X","article-title":"Progress and challenges in anti-obesity pharmacotherapy","volume":"6","author":"Bessesen","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.xcrm.2026.102743_bib11","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1111\/dom.13752","article-title":"Gaps to bridge: Misalignment between perception, reality and actions in obesity","volume":"21","author":"Caterson","year":"2019","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.xcrm.2026.102743_bib12","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1080\/17446651.2022.2110865","article-title":"A review on the beneficial effects of bariatric surgery in the management of obesity","volume":"17","author":"Abdul Wahab","year":"2022","journal-title":"Expert Rev. Endocrinol. Metab."},{"key":"10.1016\/j.xcrm.2026.102743_bib13","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g3961","article-title":"Bariatric surgery for obesity and metabolic conditions in adults","volume":"349","author":"Arterburn","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.xcrm.2026.102743_bib14","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A randomized, controlled trial of 3.0 mg of liraglutide in weight management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.102743_bib15","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-Weekly Semaglutide in Adults with Overweight or Obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.102743_bib16","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.33326","article-title":"One-Year Weight Reduction With Semaglutide or Liraglutide in Clinical Practice","volume":"7","author":"Gasoyan","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.xcrm.2026.102743_bib17","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.57349","article-title":"Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity","volume":"8","author":"Rodriguez","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.xcrm.2026.102743_bib18","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2174\/1573399812666151223093841","article-title":"Glucagon-Like Peptide-1 Receptor Agonists for Type 2 Diabetes: A Clinical Update of Safety and Efficacy","volume":"12","author":"Drab","year":"2016","journal-title":"Curr. Diabetes Rev."},{"key":"10.1016\/j.xcrm.2026.102743_bib19","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/oby.23952","article-title":"Early- and later-stage persistence with antiobesity medications: A retrospective cohort study","volume":"32","author":"Gasoyan","year":"2024","journal-title":"Obesity"},{"key":"10.1016\/j.xcrm.2026.102743_bib20","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1002\/oby.24331","article-title":"Changes in weight and glycemic control following obesity treatment with semaglutide or tirzepatide by discontinuation status","volume":"33","author":"Gasoyan","year":"2025","journal-title":"Obesity"},{"key":"10.1016\/j.xcrm.2026.102743_bib21","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1185\/03007990903421994","article-title":"Persistence with injectable antidiabetic agents in members with type 2 diabetes in a commercial managed care organization","volume":"26","author":"Cooke","year":"2010","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.xcrm.2026.102743_bib22","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s13300-013-0034-y","article-title":"Adherence to therapies in patients with type 2 diabetes","volume":"4","author":"Garc\u00eda-P\u00e9rez","year":"2013","journal-title":"Diabetes Ther."},{"key":"10.1016\/j.xcrm.2026.102743_bib23","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.2147\/PPA.S106821","article-title":"Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors","volume":"10","author":"Polonsky","year":"2016","journal-title":"Patient Prefer. Adherence"},{"key":"10.1016\/j.xcrm.2026.102743_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2022.175107","article-title":"GZR18, a novel long-acting GLP-1 analog, demonstrated positive in vitro and in vivo pharmacokinetic and pharmacodynamic characteristics in animal models","volume":"928","author":"Zhang","year":"2022","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.xcrm.2026.102743_bib25","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.regpep.2011.12.006","article-title":"Functional importance of GLP-1 receptor species and expression levels in cell lines","volume":"175","author":"Knudsen","year":"2012","journal-title":"Regul. Pept."},{"key":"10.1016\/j.xcrm.2026.102743_bib26","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1111\/dom.16285","article-title":"The safety, tolerability, pharmacokinetics and pharmacodynamics of GZR18 in healthy American and Chinese adult subjects","volume":"27","author":"Liu","year":"2025","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.xcrm.2026.102743_bib27","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/S2213-8587(23)00388-1","article-title":"Efficacy and safety of once weekly semaglutide 2\u00b74 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial","volume":"12","author":"Mu","year":"2024","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.xcrm.2026.102743_bib28","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.2337\/db25-1966-LB","article-title":"1966-LB: Efficacy and Safety of Semaglutide 7.2 mg in Obesity\u2014STEP UP Trial","volume":"74","author":"Wharton","year":"2025","journal-title":"Diabetes"},{"key":"10.1016\/j.xcrm.2026.102743_bib29","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJMoa2302392","article-title":"Daily oral GLP-1 receptor agonist orforglipron for adults with obesity","volume":"389","author":"Wharton","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.102743_bib30","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide Once Weekly for the Treatment of Obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.102743_bib31","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1111\/dom.14412","article-title":"Pharmacokinetics, safety, tolerability and efficacy of cotadutide, a glucagon-like peptide-1 and glucagon receptor dual agonist, in phase 1 and 2 trials in overweight or obese participants of Asian descent with or without type 2 diabetes","volume":"23","author":"Asano","year":"2021","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.xcrm.2026.102743_bib32","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1111\/dom.13824","article-title":"Body weight management and safety with efpeglenatide in adults without diabetes: A phase II randomized study","volume":"21","author":"Pratley","year":"2019","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.xcrm.2026.102743_bib33","doi-asserted-by":"crossref","DOI":"10.1111\/cob.12432","article-title":"Efficacy and safety of glucagon-like peptide-1\/glucagon receptor co-agonist JNJ-64565111 in individuals with obesity without type 2 diabetes mellitus: A randomized dose-ranging study","volume":"11","author":"Alba","year":"2021","journal-title":"Clin. Obes."},{"key":"10.1016\/j.xcrm.2026.102743_bib34","doi-asserted-by":"crossref","first-page":"8289","DOI":"10.1038\/s41467-023-44067-4","article-title":"A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity","volume":"14","author":"Ji","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2026.102743_bib35","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0140-6736(18)31773-2","article-title":"Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial","volume":"392","author":"O'Neil","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.xcrm.2026.102743_bib36","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1001\/jama.2024.9217","article-title":"Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial","volume":"332","author":"Zhao","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.xcrm.2026.102743_bib37","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s13300-021-01189-6","article-title":"Higher Rates of Persistence and Adherence in Patients with Type 2 Diabetes Initiating Once-Weekly vs Daily Injectable Glucagon-Like Peptide-1 Receptor Agonists in US Clinical Practice (STAY Study)","volume":"13","author":"Polonsky","year":"2022","journal-title":"Diabetes Ther."},{"key":"10.1016\/j.xcrm.2026.102743_bib38","first-page":"11","article-title":"Efficacy and safety of bofanglutide, a GLP-1 receptor agonist, in Chinese adults with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial","author":"Ji","year":"2026","journal-title":"Signal Transduct. Target Ther."},{"key":"10.1016\/j.xcrm.2026.102743_bib39","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1056\/NEJMoa2208601","article-title":"Once-Weekly Semaglutide in Adolescents with Obesity","volume":"387","author":"Weghuber","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.102743_bib40","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.3390\/molecules25081987","article-title":"Type 2 Diabetes Mellitus: A Review of Multi-Target Drugs","volume":"25","author":"Artasensi","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.xcrm.2026.102743_bib41","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.029282","article-title":"Role of Glucagon-Like Peptide-1 Receptor Agonists in Achieving Weight Loss and Improving Cardiovascular Outcomes in People With Overweight and Obesity","volume":"12","author":"Michos","year":"2023","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.xcrm.2026.102743_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.156043","article-title":"Comparative efficacy of THR-\u03b2 agonists, FGF-21 analogues, GLP-1R agonists, GLP-1-based polyagonists, and Pan-PPAR agonists for MASLD: A systematic review and network meta-analysis","volume":"161","author":"Lin","year":"2024","journal-title":"Metabolism"},{"key":"10.1016\/j.xcrm.2026.102743_bib44","unstructured":"U.S. Food and Drug Administration. Adaptive Design Clinical Trials for Drugs and Biologics: Guidance for Industry. (2019). https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/adaptive-design-clinical-trials-drugs-and-biologics-guidance-industry."}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126001606?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126001606?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T21:09:26Z","timestamp":1785964166000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379126001606"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2666379126001606"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.102743","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"GZR18, a GLP-1 analog with once-weekly or bi-weekly dosing for body weight management: A randomized, placebo-controlled, phase 1b\/2a trial","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.102743","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102743"}}